A comparative study of the amount of α-synuclein in ischemic stroke and Parkinson’s disease

Abstract

In the present study, we detected the level of oligomeric form of α-synuclein in the red blood cells of ischemic stroke, Parkinson's disease, and normal people and compared the differences to assess the diagnosis potential of α-synuclein in ischemic stroke patients. 86 ischemic stroke, 100 PD, and 102 healthy cases were enrolled in the present study. Total protein amount in the red blood cells were quantified by BCA assay using spectrophotometer. Levels of oligomeric form of α-synuclein were characterized by a sandwich ELISA. Analysis of correlation analysis and receiver operating characteristic curve were conducted. Significant differences were detected in the levels of oligomeric forms of α-synuclein in different samples' blood cells (P < 0.05); the levels of total protein in (188.1 ± 33.9 mmol/L) healthy people were significantly higher than that of PD (147.7 ± 45.0 mmol/L) and ischemic stroke groups (142.9 ± 43.0 mmol/L) (P < 0.05). There was no correlation between the age of patients and level of α-synuclein (R (2) = 0.216 in ischemic stroke group and -0.104 in PD group) and the receiver operating characteristic curve analysis showed a high sensitivity of α-synuclein in discriminating ischemic stroke (sensitivity was 63.7 % and specificity was 9.6 %) and PD (sensitivity was 44.1 % and specificity was 12.5 %) patients from the controls. The levels of oligomeric form of α-synuclein of red blood cells in ischemic stroke and Parkinson's disease patients were both significant higher than normal people. And the level of oligomeric form α-synuclein showed a potential for diagnosis of ischemic stroke in clinic.

α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise

“…The levels of total α-syn decreased with age in the whole population, consistent with the data reported for α-syn in RBCs and plasma of healthy subjects or PD patients ( Mohanty et al, 2014 ; Wang et al, 2015 ; Koehler et al, 2015 ; Zhao et al, 2016 ). Conversely, platelet Aβ levels directly correlated with age, as previously reported in RBCs ( Kiko et al, 2012 ; Daniele et al, 2017 ).…”

Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies

“…For instance, α-syn spreading to cortical regions is associated with Dementia with Lewy Bodies (DLB), while α-syn aggregates occur in both neurons and oligodendrocytes in MSA, thus contributing to a massive de-myelinization within affected brain areas [135,136]. Besides classic synucleinopathies, α-syn aggregates may be detected in a variety of disorders including Progressive Supranuclear Palsy (PSP), HD, AD, FTD, ALS, and brain ischemia [23][24][25][26]136,137]. A toxic gain of function is supposed to underlie α-syn overexpression, as confirmed by experimental models of parkinsonism including administration of METH [103,119,120,138], MPTP [139][140][141], and 6-OHDA [142,143].…”

Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease

“…Site-specific acetylation of RelA at the Lys 310 residue was necessary to switch anti-apoptotic p50/RelA, activated after a brief preconditioning ischemia and leading to brain tolerance toward the pro-apoptotic p50/RelA activated after a prolonged harmful brain ischemia (Blondeau et al, 2001;Lanzillotta et al, 2010). In this regard, studies showing that post-stroke induction of α-syn mediates ischemic brain damage (Ishimaru et al, 1998;Hu et al, 2006;Yoon et al, 2006;Unal-Cevik et al, 2011;Surgucheva et al, 2014;Kim T. et al, 2016) and that the levels of oligomeric form of α-syn of red blood cells in ischemic stroke and PD patients are both significantly higher than in controls (Zhao et al, 2016), seem to shed light on a possible link between NF-κB dysregulation and α-syn accumulation that deserves to be addressed by ad hoc studies.…”